Myomo Inc (MYO)
XASE:MYO
Want to see MYO full AI Analyst Report?
Top Page
Myomo
(NYSE MKT:MYO)
Select Model
Select Model
Rating:48Neutral
Price Target:
$0.77
▼(-10.47% Downside)
Action:Reiterated
Date:05/14/26
The score is held down primarily by weak financial performance—ongoing losses, significant negative cash flow, and elevated balance-sheet risk—despite strong revenue growth and healthy gross margins. The latest earnings call adds some support due to improving operating trends and reaffirmed guidance, but mixed technicals and loss-driven valuation keep the overall score below average.
Positive Factors
Revenue Growth & Gross Margin
Multi-year revenue acceleration (TTM ~69% growth) coupled with consistently high gross margins (~66% TTM) indicate durable product economics and pricing power. This supports long-term scalability: as fixed costs are absorbed, sustainable margins can translate rising revenue into improved operating leverage over months.
Negative Factors
Large Cash Burn & Negative Free Cash Flow
Deep, persistent negative operating and free cash flow (millions of dollars of burn) erodes runway and forces reliance on external financing. Over a 2–6 month horizon this constrains investments in commercial scale, product development, or international expansion unless operating cash generation improves or funding is secured.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth & Gross Margin
Multi-year revenue acceleration (TTM ~69% growth) coupled with consistently high gross margins (~66% TTM) indicate durable product economics and pricing power. This supports long-term scalability: as fixed costs are absorbed, sustainable margins can translate rising revenue into improved operating leverage over months.
Read all positive factors
Myomo (MYO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$32.42M
Dividend YieldN/A
Average Volume (3M)328.72K
Price to Earnings (P/E)―
Beta (1Y)1.46
Revenue Growth6.68%
EPS Growth-146.95%
CountryUS
Employees184
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.36
Shares Outstanding38,638,653
10 Day Avg. Volume423,107
30 Day Avg. Volume328,721
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.34
Price to Sales (P/S)0.93
P/FCF Ratio-2.34
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue1.01
Enterprise Value/Gross Profit1.53
Enterprise Value/Ebitda-3.26
Forecast
1Y Price Target
$4.32Price Target Upside402.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$44.21M
Myomo Business Overview & Revenue Model
Company Description
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis ...
How the Company Makes Money
Myomo makes money primarily by selling and providing its wearable myoelectric orthosis devices (notably the MyoPro) to patients, typically through the clinical prescription and fitting process. Revenue is generated from the delivered device and as...
Myomo Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call highlights steady, incremental progress: modest top-line growth (Q1 revenue +3%), improved gross margin (+100 bps), lower operating expenses (-1%), improved adjusted EBITDA (negative $2.3M vs negative $2.8M), strong shifts toward recurring revenue (49% of revenue vs 25% prior year), and robust international and O&P channel growth (international +53% YoY; U.S. O&P +79% YoY). Management provided constructive operational updates including payer contracting (covered lives up to 158M), product advances (mobile app reducing material costs ~10%, MyoPro 3 development), and a growing referral network (150+ rehab facilities, Autoboc partnership). Lowlights include continued net losses, dependency on a multi-quarter revenue cycle, macro pressures in Medicare Advantage and a decline in Medicare Part B dollar contribution, and some short-term margin pressure from higher on-site fitting costs. Overall, positive operational momentum and improving financial metrics outweigh remaining profitability and execution risks.Positive Updates
Modest Revenue Growth
Q1 2026 revenue of $10.1M, up 3% year-over-year; company reiterated full-year revenue guidance of $43M–$46M.
Negative Updates
Continued Net Loss and Negative EBITDA
Net loss of $3.0M ($0.07 per share) in Q1 and adjusted EBITDA still negative at $2.3M, indicating the company remains unprofitable while on a path toward improvement.
Read all updates
Q1-2026 Updates
Positive
Negative
Modest Revenue Growth
Q1 2026 revenue of $10.1M, up 3% year-over-year; company reiterated full-year revenue guidance of $43M–$46M.
Read all positive updates
Company Guidance
Myomo guided Q2 revenue of $10.3 million to $10.8 million (up ~7%–12% year‑over‑year and ~2%–7% sequentially), said Q2 gross margin should be higher year‑over‑year but lower sequentially (largely due to channel mix) and noted a ~10% reduction in MyoPro material costs from a new mobile app will begin flowing through to gross margin in Q2; operating expenses are expected to increase slightly versus Q1 to support modestly higher advertising, and full‑year revenue guidance was reiterated at $43 million to $46 million with a goal to cap 2026 operating expense growth at about one‑half the rate of revenue growth.Myomo Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
40
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 41.21M | 40.93M | 32.55M | 19.24M | 15.56M | 13.86M |
| Gross Profit | 27.18M | 26.89M | 23.19M | 13.18M | 10.25M | 10.31M |
| EBITDA | -12.72M | -12.64M | -5.04M | -7.71M | -10.13M | -9.93M |
| Net Income | -15.12M | -15.57M | -6.18M | -8.15M | -10.72M | -10.37M |
Balance Sheet | ||||||
| Total Assets | 36.75M | 38.64M | 42.24M | 14.58M | 10.16M | 20.10M |
| Cash, Cash Equivalents and Short-Term Investments | 15.70M | 18.39M | 24.87M | 8.87M | 5.35M | 15.52M |
| Total Debt | 18.96M | 19.38M | 8.11M | 601.30K | 553.91K | 735.00K |
| Total Liabilities | 27.75M | 27.23M | 17.53M | 5.59M | 3.80M | 4.69M |
| Stockholders Equity | 9.00M | 11.40M | 24.71M | 8.99M | 6.36M | 15.41M |
Cash Flow | ||||||
| Free Cash Flow | -17.34M | -16.25M | -4.65M | -6.32M | -10.35M | -9.87M |
| Operating Cash Flow | -14.03M | -14.51M | -3.29M | -6.17M | -10.23M | -9.55M |
| Investing Cash Flow | -5.66M | -7.06M | 259.98K | -2.03M | -310.79K | -326.46K |
| Financing Cash Flow | 11.46M | 11.43M | 20.93M | 9.71M | 376.86K | 13.17M |
Myomo Technical Analysis
Positive
0.86
Price Trends
0.77
Positive
0.82
Positive
0.92
Negative
Market Momentum
0.02
Positive
55.25
Neutral
68.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYO, the sentiment is Positive. The current price of 0.86 is above the 20-day moving average (MA) of 0.84, above the 50-day MA of 0.77, and below the 200-day MA of 0.92, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 55.25 is Neutral, neither overbought nor oversold. The STOCH value of 68.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MYO.
Myomo Risk Analysis
Myomo disclosed 16 risk factors in its most recent earnings report. Myomo reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Myomo Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $32.42M | -2.37 | -114.87% | ― | 6.68% | -146.95% | |
47 Neutral | $48.61M | -2.56 | 836.32% | ― | 31.90% | -10.81% | |
46 Neutral | $19.62M | -0.91 | -312.04% | ― | -100.00% | 100.00% | |
42 Neutral | $5.70M | -0.16 | -247.60% | ― | ― | 36.00% | |
42 Neutral | $16.22M | ― | -279.06% | ― | ― | 25.24% |
* Healthcare Sector Average
MYO
Myomo
0.88
-2.48
-73.87%
ECOR
Electrocore
5.91
0.60
11.21%
MODD
Modular Medical
3.33
-23.29
-87.49%
RBOT
Vicarious Surgical
0.84
-6.51
-88.57%
ADGM
Adagio Medical Holdings
0.84
-0.35
-29.24%
IINN
Inspira Technologies Oxy BHN
0.38
-0.13
-25.49%
Myomo Corporate Events
Business Operations and StrategyExecutive/Board Changes
Myomo Adds Horton Capital Executive to Board of Directors
Positive
May 13, 2026
Myomo, a wearable medical robotics company specializing in the MyoPro upper-limb orthosis for patients with neurological disorders and paralysis, is based in Burlington, Massachusetts and serves U.S. and international markets through its sales and...
Business Operations and StrategyExecutive/Board Changes
Myomo Adds Will Febbo to Board for Growth
Positive
Apr 16, 2026
On April 14, 2026, Myomo appointed William “Will” Febbo to its Board of Directors as a Class II director, expanding the board to six members and positioning him to serve until the 2028 annual meeting of stockholders. Febbo, an experien...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.